Restoring synaptic function in Down Syndrome mice
恢复唐氏综合症小鼠的突触功能
基本信息
- 批准号:9340289
- 负责人:
- 金额:$ 23.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAngelman SyndromeBehaviorBehavioralBiological MarkersBrainBreedingChronicCognitiveCognitive deficitsCommunicationComplexCrossbreedingDown SyndromeFunctional disorderFutureGeneticGlutamatesGoalsHereditary DiseaseImpaired cognitionImpairmentInterventionKnock-in MouseLeadLearningLong-Term DepressionLong-Term PotentiationMemoryMental DepressionModelingMolecularMusMutant Strains MiceMutationNeurotransmittersNitric OxidePatientsPharmacological TreatmentPharmacologyPhosphorylationPublishingReactive Oxygen SpeciesRegimenSynapsesSynaptic plasticitySyndromeSystemTestingTherapeuticTreatment ProtocolsWorkantioxidant therapybrain cellcalmodulin-dependent protein kinase IIcognitive functionfear memorygenetic approachimprovedinsightmouse modelnovelnovel therapeutic interventionnovel therapeuticsoxidationrestorationscreeningsuccesssynaptic functiontooltransmission processunpublished works
项目摘要
Project Summary
Down Syndrome (DS) model mice have three abnormalities in synaptic functions that can
explain the cognitive deficits in DS: Decreased long-term potentiation (LTP) and enhanced long-
term depression (LTD) of glutamatergic synapses, as well as enhanced inhibitory transmission
at GABAergic synapses. Our recent published work indicates that all three observed synaptic
dysfunction should be caused by the hyper-phosphorylation of the Ca2+/calmodulin-dependent
protein kinase II (CaMKII) seen in DS mice. Our recent unpublished work indicates an
intriguing possible mechanism for the cause of CaMKII hyper-phosphorylation in the DS mice.
Importantly, this mechanism could also be targeted by pharmacological intervention.
As a proof of principle, this project will focus on two aspects of the overall question:
(Aim 1) Testing the underlying cause for CaMKII hyper-phosphorylation in DS mice (using a
new mutant mouse line that has been generated in the lab and that is incompetent for the
proposed underlying mechanism);
(Aim 2) Restoration of normal LTP by genetic reversal of T305/306 hyper-phosphorylation in
DS mice (using a CaMKII T305/306AV mutant mouse line currently available to the lab).
Future studies will test restoration of the other synaptic dysfunctions in DS, restoration of
cognitive behavioral tasks, and restoration also by pharmacological means.
Notably, while it may seem preposterous to propose a reversal of cognitive impairments in a
very complex syndrome by a rather simple intervention, there is actually prior precedent for
success: In a model of a different genetic condition that causes cognitive impairments,
Angelman Syndrome (AS), CaMKII is also hyper-phosphorylated, and even heterozygous
T305/306AV mutation was sufficient to restore both normal LTP and spatial learning. In
contrast to AS, the hyper-phosphorylation of CaMKII in DS could be targeted also
pharmacologically (if our hypothesized underlying mechanism is correct). Thus, this project will
not only provide significant further insight into the mechanism underlying normal synaptic
functions and their impairments in DS, but also has tremendous potential for directly opening a
new therapeutic avenue for restoring cognitive functions in patients with DS.
项目摘要
唐氏综合征(DS)模型小鼠的突触功能有三种异常,
解释DS中的认知缺陷:长时程增强(LTP)降低和长时程增强(LTP)增强。
突触的延迟抑制(LTD),以及增强的抑制性传递
GABA能突触我们最近发表的工作表明,所有三个观察到的突触
功能障碍应该是由Ca 2 +/钙调蛋白依赖性的过度磷酸化引起的。
蛋白激酶II(CaMKII)。我们最近未发表的研究表明,
引起DS小鼠中CaMK II过度磷酸化的可能机制。
重要的是,这种机制也可以通过药物干预来靶向。
作为一项原则证明,该项目将侧重于整个问题的两个方面:
(Aim 1)测试DS小鼠中CaMK II过度磷酸化的根本原因(使用
实验室中产生的新突变小鼠品系,
(一)基本机制;
(Aim 2)通过T305/306过度磷酸化的遗传逆转恢复正常LTP。
DS小鼠(使用实验室目前可用的CaMKII T305/306 AV突变小鼠系)。
未来的研究将测试DS中其他突触功能障碍的恢复,
认知行为任务和恢复也通过药理学手段。
值得注意的是,虽然提出逆转认知障碍似乎是荒谬的,
非常复杂的综合征通过一个相当简单的干预,实际上有先例,
成功:在导致认知障碍的不同遗传条件的模型中,
Angelman综合征(AS),CaMKII也是过度磷酸化的,甚至是杂合的
T305/306 AV突变足以恢复正常的LTP和空间学习。在
与AS相比,DS中CaMKII的过度磷酸化也可以被靶向
(如果我们假设的潜在机制是正确的)。因此,该项目将
不仅为进一步了解正常突触的机制提供了重要的线索,
功能及其在DS中的损伤,而且还具有直接打开
恢复DS患者认知功能的新治疗途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
K. Ulrich Bayer其他文献
K. Ulrich Bayer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('K. Ulrich Bayer', 18)}}的其他基金
CaMKII in global cerebral ischemia: mechanisms and therapeutic intervention
CaMKII 在全脑缺血中的作用:机制和治疗干预
- 批准号:
10531925 - 财政年份:2021
- 资助金额:
$ 23.33万 - 项目类别:
CaMKII in global cerebral ischemia: mechanisms and therapeutic intervention
CaMKII 在全脑缺血中的作用:机制和治疗干预
- 批准号:
10328983 - 财政年份:2021
- 资助金额:
$ 23.33万 - 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
- 批准号:
10222559 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
- 批准号:
10454912 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
- 批准号:
10671685 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
- 批准号:
10444721 - 财政年份:2020
- 资助金额:
$ 23.33万 - 项目类别:
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunction
β淀粉样蛋白诱导的突触功能障碍中的突触后激酶/磷酸酶网络
- 批准号:
10450777 - 财政年份:2018
- 资助金额:
$ 23.33万 - 项目类别:
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunction
β淀粉样蛋白诱导的突触功能障碍中的突触后激酶/磷酸酶网络
- 批准号:
10207804 - 财政年份:2018
- 资助金额:
$ 23.33万 - 项目类别:
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunction
β淀粉样蛋白诱导的突触功能障碍中的突触后激酶/磷酸酶网络
- 批准号:
9791023 - 财政年份:2018
- 资助金额:
$ 23.33万 - 项目类别:
Restoring synaptic function in Down Syndrome mice
恢复唐氏综合症小鼠的突触功能
- 批准号:
9243583 - 财政年份:2016
- 资助金额:
$ 23.33万 - 项目类别:
相似国自然基金
天使症候群(Angelman Syndrome,AS)TrkB信号损伤的机制研究及靶向干预
- 批准号:31371139
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
相似海外基金
The Role of Sensory Receptors in Angelman Syndrome
感觉感受器在天使综合症中的作用
- 批准号:
10630683 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Small Molecule Therapeutic Discovery for Angelman Syndrome
天使综合症的小分子治疗发现
- 批准号:
10636253 - 财政年份:2023
- 资助金额:
$ 23.33万 - 项目类别:
Interaction of Myelin-Axon reveled new pathological mechanism in angelman syndrome
髓鞘-轴突的相互作用揭示了天使综合征的新病理机制
- 批准号:
22K07868 - 财政年份:2022
- 资助金额:
$ 23.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Determining minimal clinically important differences for neurodevelopmental outcome measures in Angelman syndrome
确定天使综合征神经发育结果测量的最小临床重要差异
- 批准号:
10186591 - 财政年份:2021
- 资助金额:
$ 23.33万 - 项目类别:
Determining minimal clinically important differences for neurodevelopmental outcome measures in Angelman syndrome
确定天使综合征神经发育结果测量的最小临床重要差异
- 批准号:
10396549 - 财政年份:2021
- 资助金额:
$ 23.33万 - 项目类别:
Gene Therapy Rescue of Angelman Syndrome with Reelin
Reelin 基因疗法拯救天使综合症
- 批准号:
10317654 - 财政年份:2021
- 资助金额:
$ 23.33万 - 项目类别:
Contribution of GABA-A receptor subunit deletions to Angelman syndrome pathophysiology
GABA-A 受体亚基缺失对 Angelman 综合征病理生理学的贡献
- 批准号:
10391880 - 财政年份:2021
- 资助金额:
$ 23.33万 - 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
- 批准号:
10490828 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
- 批准号:
10237150 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
- 批准号:
10011898 - 财政年份:2019
- 资助金额:
$ 23.33万 - 项目类别:














{{item.name}}会员




